Compare Vanguard Mega Cap Growth ETF (MGK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Merck & Co., Inc. — how do they compare? Vanguard Mega Cap Growth ETF trades at $86.85 (market cap $35B), while Merck & Co., Inc. trades at $149.52 (market cap $368.89B). The key difference: Merck & Co., Inc. is far larger — about 10.5× Vanguard Mega Cap Growth ETF's market cap, and Merck & Co., Inc. pays a 2.27% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 50 Days and Merck & Co., Inc. for 97 Days on average.
| MGK | MRK | |
|---|---|---|
Market Cap | $35B | $368.89B |
Volume | 2,595,698 | 12,302,857 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $156.43 |
52-Week Low | $70.70 | $82.49 |
Typical Hold Time | 50 Days | 97 Days |
Enterprise Value | — | $415.66B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $86.85, down 3.1% over the past day amid a bearish technical signal, though moving averages remain bullish. The fund offers exposure to large-cap U.S. growth stocks like Nvidia and Apple, with a low expense ratio of 0.05%. Recent news highlights its strong five-year returns and suitability for long-term growth investors, despite higher volatility compared to broader indices.
The outlook for MGK is mixed; its concentrated tech holdings provide growth potential but increase sensitivity to sector swings. Risks include market volatility and sector concentration, while opportunities lie in its historical outperformance and cost efficiency. Investors should weigh its growth focus against diversification needs.
MRK trades at $149.52, up 2.18% today, with a bearish technical signal but strong fundamental performance. The company reported a string of earnings beats, with Q3 2026 EPS of $2.49 exceeding the $2.09 estimate. Revenue for 2025 was $65.01B, with a net income margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals, a strategic move to bolster its oncology pipeline.
The outlook is supported by a strong analyst consensus with a $159.95 price target, though high valuation ratios and a projected decline in 2026 net income to $2.5B present risks. The stock offers a dividend yield from its upcoming $0.85 payment, but investors must weigh acquisition integration challenges against long-term growth potential in a competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
